Mankind Pharma Limited (NSE:MANKIND)
India · Delayed Price · Currency is INR 2,038.80
+14.80 (0.73%)
At close: Mar 27, 2026
Mankind Pharma Revenue
Mankind Pharma had revenue of 35.67B INR in the quarter ending December 31, 2025, with 10.44% growth. This brings the company's revenue in the last twelve months to 139.14B, up 19.53% year-over-year. In the fiscal year ending March 31, 2025, Mankind Pharma had annual revenue of 122.07B with 18.98% growth.
Revenue (ttm)
139.14B
Revenue Growth
+19.53%
P/S Ratio
6.05
Revenue / Employee
7.09M
Employees
19,620
Market Cap
841.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 122.07B | 19.47B | 18.98% |
| Mar 31, 2024 | 102.60B | 15.11B | 17.27% |
| Mar 31, 2023 | 87.49B | 9.68B | 12.44% |
| Mar 31, 2022 | 77.82B | 15.67B | 25.22% |
| Mar 31, 2021 | 62.14B | 3.43B | 5.83% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Cipla | 279.67B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
| Emcure Pharmaceuticals | 88.50B |